Inhibition of the Progesterone Nuclear Receptor during the Bone Linear Growth Phase Increases Peak Bone Mass in Female Mice
Figure 8
Bone mass and bone formation changes with RU486 treatment.
One month-old female WT mice were treated with vehicle or RU486 (500 µg/d, 5x/week for two months). MicroCT was performed at the distal femurs to measure the cancellous bone volume (A). Bone formation was measured in either serum (P1NP, B) or at the distal femurs by surface-based bone histomorphometry (bone formation rate/bone surface, BFR/BS; C). Bone resorption was measured in the urine (DPD/Cr, D), at the distal femurs by surface-based bone histomorphometry (osteoclast surface, Oc.S/BS; E) and from bone marrow osteoclastic cultures (TRAP+, F). *p<0.05 compared with WT.